Sökning: id:"swepub:oai:DiVA.org:uu-133128" >
Longterm follow-up ...
Longterm follow-up after transarterial chemotherapy for hepatocellular carcinoma in a Scandinavian centre
-
- Norén, Agneta (författare)
- Uppsala universitet,Gastrointestinalkirurgi
-
- Urdzik, Jozef (författare)
- Uppsala universitet,Gastrointestinalkirurgi
-
- Duraj, Frans (författare)
- Uppsala universitet,Gastrointestinalkirurgi
-
visa fler...
-
- Ebeling Barbier, Charlotte (författare)
- Uppsala universitet,Enheten för radiologi
-
- Karlson, Britt-Mari (författare)
- Uppsala universitet,Gastrointestinalkirurgi
-
- Haglund, Ulf (författare)
- Uppsala universitet,Gastrointestinalkirurgi
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2010
- 2010
- Engelska.
-
Ingår i: HPB. - : Elsevier BV. - 1365-182X. ; 12:9, s. 637-643
- Relaterad länk:
-
http://www.hpbonline...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Transarterial chemotherapy infusion (TAI) with lipiodol is a palliative treatment for hepatocellular carcinoma. The aim of this study was to describe the outcomes of TAI from a single scandinavian centre between 1995 to 2008. Methods: The study is a retrospective analyse of prospectively collected data. TAI (doxorubicin, 50 mg with lipiodol) was administrated every 6 weeks. After 5 treatments, a CT scan was performed, and if the disease was stable, (RECIST score) treatment was continued. Results: 57 patients with HCC were treated with TAI. Median age; 72 years (52-84), 41 (71%) men. 52 (91%) had Child-Pugh score A, and 5 (9%) had Child-Pugh B. Nine (16%) patients had a BCLC score A, 19 (33%) B, 29 (51%) C, while none was classified as BCLC D. Twenty nine (51%) patients had a tumour size ≥ 10 cm. In total 254 treatments were performed, a median of 4 (1-20) per patient. Treatment mortality was 0%. In 30 (53%) patients the treatment strategy was not completed due to deteriorating clinical conditions. Median survival was 17 months (2-108), 2, 3, and 5-years survival was 34%, 22%, and 13%, respectively. Patients that responded to treatment (n = 23) had a median survival of 26 (13-108) months compared to 8 (2-48) months for those not fulfilling the treatment plan, p < 0.05. Tumour size ≥ 10 cm, AFP ≥ 400 μg/l, and Child-Pugh class B or C were negative prognostic factors for survival, p < 0.05. Conclusions: The 5 year survival was 13%, and median survival 17 months. Treatment mortality was 0%. Patients that responded to treatment (40%) had a median survival of 26 months. TAI provides good palliation but selection of patients is crucial.
Nyckelord
- transarterial chemotherapy
- hepatocellular carcinoma < liver
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
HPB
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas